Medicamen Organics Peer Comparison

NSE: MEDIORG

₹26.75

₹0.00 (0.00%)

As on 16-Oct-2026IST

Market cap

₹40 Cr

Revenue (TTM)

₹23 Cr

P/E Ratio

--

P/B Ratio

1.3

Div. Yield

0 %

Edit

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	40	34,586	25,275	16,073	14,003
Revenue (₹ Cr)	23	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	-4.02	1,018.97	497.77	603.02	270.18
Net Margin (%)	-17.70	10.47	20.72	22.63	23.29
RoE (%)	-13.83	21.30	28.49	19.61	14.45
Price to Earnings	--	34.20	50.78	26.65	50.85
Price-To-Book	1.27	6.61	12.50	4.61	6.75

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	22.63	9,203.54	2,022.99	2,551.83	1,054.89
Total Income	22.71	9,335.01	2,053.15	2,612.24	1,107.25
Total Expenditure	26.25	7,457.80	1,448.49	1,754.55	686.95
EBITDA	-3.62	1,745.74	574.50	797.28	367.94
Depreciation	0.90	415.05	91.74	75.36	74.46
EBIT	-4.52	1,330.70	482.76	721.93	293.48
Interest	0.84	143.67	23.95	5.37	0.82
Other Income	0.08	131.47	30.17	60.41	52.36
Exceptional Items	--	-31.35	--	-25.66	-3.28
Profit before Tax	-5.28	1,287.14	488.98	751.31	344.65
Provision for Tax	-1.26	345.87	124.98	186.83	85.42
Profit after Tax	-4.02	941.27	364.00	564.48	259.23

Liabilities (₹ Cr)

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	28.73	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	-0.14	26.64	--	--	-1.92
Non-Current Liabilities	1.19	584.19	345.47	142.73	47.58
Current Liabilities	21.75	3,912.24	710.20	682.24	169.08
Total Liabilities	51.63	9,514.48	2,930.14	4,157.10	2,231.79

Assets (₹ Cr)

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	14.67	3,861.01	1,447.01	1,333.54	981.68
Current Assets	36.86	5,612.10	1,483.13	2,823.56	1,250.11
Total Assets	51.63	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	14.29	1,204.08	196.61	0.00	0.00
Net Current Assets	15.11	1,699.86	772.93	2,141.33	1,081.03
Contingent Liabilities	0.96	258.92	13.18	4.82	3.76

Cashflow (₹ Cr)

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	-4.60	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-1.72	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	3.48	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	-2.83	93.92	-56.08	-69.08	11.28

Ratios

Profitability Ratios

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	-10.38	25.25	27.50	24.61	18.04
ROE (%)	-13.83	20.09	21.43	18.41	13.54
ROA (%)	-7.26	10.70	14.25	14.27	12.15
EBIT Margin (%)	-15.65	20.40	29.89	33.61	39.84
Net Margin (%)	-17.70	10.08	17.73	21.61	23.41
Cash Profit Margin (%)	-13.80	14.44	22.53	24.81	31.63

Growth Ratios

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	-40.74	16.56	36.98	6.91	-12.10
EBIT Growth (%)	-152.78	21.77	75.89	19.60	-23.76
Net Profit Growth (%)	-199.32	33.05	39.94	16.24	-30.25
EPS Growth (%)	-195.51	35.59	39.94	16.05	-29.80
Book Value Growth (%)	-2.22	11.36	22.95	18.43	11.27

Valuation Ratios

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	0.00	32.73	42.34	21.18	40.73
Price / Book Value	0.89	6.13	8.23	3.60	5.27
Dividend Yield (%)	0.00	0.23	0.28	0.51	0.74
EV/EBITDA	-10.92	16.68	25.23	13.94	25.25
Market Cap (₹ Cr)	25.67	30,257.56	15,412.11	11,956.86	10,627.92

Solvency Ratios

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.50	0.24	0.10	0.00	0.00
Short term debt to equity ratio	0.46	0.16	--	--	--
Current Ratio	1.69	1.43	2.09	4.14	7.39
Quick Ratio	1.21	0.82	1.37	3.12	5.46
Interest Coverage	-5.29	9.96	21.42	140.86	419.57

Operating Efficiency Ratios

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	82.30	27.84	26.76	42.05	43.63
Asset Turnover	0.41	1.07	0.79	0.65	0.49
Receivable days	358.68	88.68	77.32	144.58	169.86
Inventory Days	145.22	84.11	80.83	96.67	97.92
Payable days	384.50	176.65	125.94	135.45	159.68
Cash Conversion Cycle	119.39	-3.86	32.22	105.80	108.11